CVS' Health Care Benefit arm shines in Q2, driven by government plans, even as ACA exit and utilization pressures weigh.
CVS Health (CVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cramer Loves These Dividend Stocks

09:31am, Monday, 01'st Sep 2025
Key Points Jim Cramer's Mad Money offers insights valuable to income investors, despite his broader focus on growth.
My watchlist outperformed SPY and VYM since July 1st, offering higher yield and competitive total returns, despite trailing benchmarks year-to-date. The strategy focuses on high-quality, attractively
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and HealthEquity (HQY). But which of these two stocks presents investors with the better
CVS Health advances with Aetna margin recovery, digital investments and cost savings, making it the stronger healthcare bet over Elevance.
CVS Health's Q2 Health Services revenues climb 10%. Yet, AOI slips as cost pressures and Oak Street's rising MBR ail.
'Mad Money' host Jim Cramer takes a look at CVS and what is driving the stock up.
'Mad Money' host Jim Cramer takes a look at CVS and what is driving the stock up.

The Big 3: LLY, BA, CVS

12:01pm, Friday, 22'nd Aug 2025
Dan Deming considers Friday's trading action after Jerome Powell's Jackson Hole speech "remarkable." On stocks he's watching ahead, he expects Eli Lilly (LLY) to rebound off a significant sell-off, Bo
CVS Health's Pharmacy & Consumer Wellness unit posts double-digit revenue gains despite ongoing reimbursement headwinds.
StoneCo, CVS, Integer Holdings and USANA emerge as attractive value stocks with low cash-flow ratios and solid growth outlooks.
StoneCo, CVS Health, KT, KB Financial and USANA Health stand out as undervalued picks with low P/B ratios and solid growth prospects.
CVS Health Inc. CVS said it will not add Gilead Sciences Inc.'s GILD new HIV prevention drug Yeztugo to its commercial plans.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE